Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 105 for:    egcg

Epigallocatechin Gallate Lowers Circulating Catecholamine Concentrations and Alters Lipid Metabolism.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03199430
Recruitment Status : Completed
First Posted : June 27, 2017
Last Update Posted : June 27, 2017
Sponsor:
Information provided by (Responsible Party):
Liam WIlliams, Swansea University

Brief Summary:
The aim of this study was to explore the impact of acute ingestion of the polyphenol epigallocatechin galate (EGCG) on catecholamine, catecholamine metabolite, systemic metabolic and cardio-vascular variables across a range of exercise intensities during graded cycle exercise in man.

Condition or disease Intervention/treatment Phase
EGCG Influence on Catecholamine Metabolism Dietary Supplement: Epigallocatechin gallate Dietary Supplement: Placebo Phase 4

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Official Title: The Polyphenol Epigallocatechin Gallate Lowers Circulating Catecholamine Concentrations and Alters Lipid Metabolism During Graded Exercise in Man.
Study Start Date : September 2015
Actual Primary Completion Date : January 2016
Actual Study Completion Date : February 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Placebo
1450mg Corn flour
Dietary Supplement: Placebo
1450mg Corn Flour

Active Comparator: Epigallocatechin gallate
1450mg Epigallocatechin gallate
Dietary Supplement: Epigallocatechin gallate



Primary Outcome Measures :
  1. change in Adrenaline & Noradrenaline concentrations (nmol.l-1) [ Time Frame: Relativised to each metabolic domain; rest, 2 hours post ingestion, highest lipid oxidation rate during exercise, lactate threshold and VO2peak (participant dependant) ]
    Changes in Adrenaline & Noradrenaline concentrations (nmol.l-1) from rest to exhaustion under EGCG and placebo conditions.

  2. Changes in Metanephrine and Normetanephrine (pmol.l-1) [ Time Frame: Relativised to each metabolic domain; rest, 2 hours post ingestion, highest lipid oxidation rate during exercise, lactate threshold and VO2peak (participant dependant) ]
    Changes in Metanephrine & Normetanephrine concentrations (pmol.l-1) from rest to exhaustion under EGCG and placebo conditions.

  3. Changes in lipid and carbohydrate oxidation (g.min-1) [ Time Frame: Over a period of approximately 2 and a half hours with the data collected relativised to each metabolic domain; rest, highest lipid oxidation rate during exercise, lactate threshold and VO2peak (participant dependant) ]
    Changes in lipid and carbohydrate oxidation (g.min-1) from rest to exhaustion under EGCG and placebo conditions.


Secondary Outcome Measures :
  1. Changes in blood glucose concentrations (mmol.l-1) [ Time Frame: Relativised to each metabolic domain; rest, two hours post ingestion, highest lipid oxidation rate during exercise, lactate threshold and VO2peak (participant dependant) ]
    Changes in glucose concentrations (pmol.l-1) from rest to exhaustion under EGCG and placebo conditions.

  2. Changes in exercise performance (S) under EGCG and placebo conditions. [ Time Frame: over a period of approximately 30 minutes from rest to volitional exhaustion. ]
    Changes in markers of exercise performance, (performance time) under EGCG and placebo conditions

  3. Changes in blood lactate concentrations (mmol.l-1) [ Time Frame: Relativised to each metabolic domain; rest, two hours post ingestion, highest lipid oxidation rate during exercise, lactate threshold and VO2peak (participant dependant) ]
    Changes in lactate concentrations (pmol.l-1) from rest to exhaustion under EGCG and placebo conditions.

  4. Changes in exercise performance (W) under EGCG and placebo conditions. [ Time Frame: over a period of approximately 30 minutes from rest to volitional exhaustion. ]
    Changes in markers of exercise performance, (maximal power obtained) under EGCG and placebo conditions



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age 18-35 years old. Caffeine intake ≤400 mg.d-1 (thus less than four cups of tea/ coffee or caffeinated soda beverages).

Habitual participation in exercise three to five times per week for 30-90 minutes per formal exercise session.

Exclusion Criteria:

  • Female Any injury, assessed via health screening questionnaire prior to the start of the study.

Publications:
Layout table for additonal information
Responsible Party: Liam WIlliams, Postgraduate Student, Swansea University
ClinicalTrials.gov Identifier: NCT03199430     History of Changes
Other Study ID Numbers: PG/2014/28
First Posted: June 27, 2017    Key Record Dates
Last Update Posted: June 27, 2017
Last Verified: June 2017

Keywords provided by Liam WIlliams, Swansea University:
catecholamines
Exercise
lipid metabolism

Additional relevant MeSH terms:
Layout table for MeSH terms
Epigallocatechin gallate
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Antimutagenic Agents
Anticarcinogenic Agents
Antineoplastic Agents
Neuroprotective Agents